Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 5, 2009

AstraZeneca Taps Jubilant for Discovery Work

  • Jubilant Biosys entered a research collaboration agreement with AstraZeneca, which will initially focus on the neuroscience area. Under the shared risk-reward collaboration, Jubilant is tasked with delivering a steady stream of discovery programs to AstraZeneca.

    The goal is to provide AstraZeneca with four to six preclinical programs, which could lead to one to two preclinical candidates per year for the initial five-year period, according to Seema Ahuja, media spokesperson for Jubilant.

    AstraZeneca will have global ownership of the compounds developed under the collaboration. Jubilant will be eligible to receive research funding, spanning an initial five-year period. In addition, AstraZeneca will also pay success-based development milestones as well as royalties on global commercialization of any compound.

    Jubilant Biosys provides integrated drug discovery and development solutions with a facility in Bangalore. The center houses over 300 scientists specializing in disciplines ranging from discovery biology, toxicology, and information technology.

     


    ♦♦♦
    Related AstraZeneca Deals:

    Palatin and AstraZeneca Expand Partnership in Obesity Drug R&D (Dec. 9, 2008)
    AstraZeneca and Singapore Institutions Ally to Develop Drugs for Liver Cancer (Aug. 15, 2008)
    AstraZeneca Taps Cenix for RNAi Drug Discovery (Mar. 19, 2008)
    Silence Therapeutics Could Earn $400M in siRNA Partnership with AstraZeneca (July 6, 2007)
    BioFocus DPI and AstraZeneca Sign Second Discovery Transaction (Apr. 19, 2007)



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »